Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Follow this link:
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DISC-3405 for the treatment of patients with polycythemia vera (PV).

Link:
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market

NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced the acquisition of all the issued and outstanding common shares of Aimia Pet Healthco Inc. (‘Aimia’). Better Choice will now be in a position to manage the clinical trials internally in hopes to develop a supplement to support weight loss in domestic animals.

Read this article:
Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market

A New Gig in the Science World – The New York Times

Good morning. Its Wednesday. Well meet the new president and chief executive of a foundation that backs stem cell research. Well also get details on a $5 million fine in a New Jersey tax break scandal.

Jennifer Raab heard about the space launch while being interviewed for a job at the New York Stem Cell Foundation that unexpectedly turned emotional.

Valentina Fossati, a scientist with the foundation, mentioned that test tubes would be part of the payload on a private mission to the International Space Station. The test tubes would contain three-dimensional models of brain tissue that scientists at the foundation had made from stem cells. Fossati said the scientists hoped to learn whether space was the place to study neurodegenerative diseases like Parkinsons disease and multiple sclerosis.

Then Fossati said that she had M.S. herself.

That was very moving, Raab said, to realize that someone had turned her own challenges into working on solving a problem for the general population.

Raab was hired as president and chief executive of the foundation. The space mission was launched on her third day on the job. The project, conducted in collaboration with other research institutions, will study the cells when they are brought back to earth. The researchers will look for changes brought on by microgravity in space and whether such changes could be applied to work on diseases like Parkinsons or M.S.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

See more here:
A New Gig in the Science World - The New York Times

Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. – InvestorsObserver

Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. "Revolutionizing Regenerative Medicine: The Booming Frontier of Synthetic Stem Cells Unleashes Hope and Healing" PMI Leads the Way

Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- According to the recent research study, the Synthetic Stem Cells Market size was valued at about USD 8.9 Billion in 2024 and expected to grow at CAGR of 23.3% to extend a value of USD 60.1 Billion by 2034.

What is Synthetic Stem Cells?

Synthetic stem cells can be designed in laboratories by mimicking the properties of natural stem cells, such as their self-renewal capacity and pluripotency (ability to differentiate into multiple cell types). These artificial cells are often created using bioengineering techniques and may involve the use of biomaterials, genetic manipulation, or other advanced technologies. The field of synthetic stem cells holds promise for various medical applications, including regenerative medicine, tissue engineering, and disease treatment. By harnessing the potential of synthetic stem cells, researchers aim to develop innovative therapies for conditions such as injuries, degenerative diseases, and other disorders that involve damaged or malfunctioning tissues.

Driving Factors:

Restrain Factors:

Get Access to Free Sample Research Report with Latest Industry Insights:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3911

*Note: PMI Sample Report includes,

Report scope:

By Region - North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Top Leading Players in Synthetic Stem Cells Market:

Download PDF Brochure:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/3911

Emerging Trends and Opportunities in Synthetic Stem Cells Market:

Challenges of Synthetic Stem Cells Market:

Detailed Segmentation:

Key highlights of the Synthetic Stem Cells Market:

Any query or customization before buying:

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/3911

Explore More Insights:

Blog: http://www.prophecyjournals.com

Follow us on:

LinkedIn | Twitter | Facebook | YouTube

See the article here:
Synthetic Stem Cells Market Size & Share to Exceed USD 60.1 Billion by 2034, at CAGR of 23.3%. - InvestorsObserver

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma and Ian Somaiya, chief financial officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 1:00 p.m. ET.

Visit link:
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK…

Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127

Read the original post:
Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK...

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

More:
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

View original post here:
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.

Continue reading here:
Revolution Medicines to Participate in Upcoming Investor Conferences